3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Prostatic Neoplasms
2
Polycystic Ovary Syndrome
2
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Stomatitis
1
Sarcopenia
1
Precancerous Conditions
1
Papillomavirus Infections
1
Pain
1
Leukemia
1
Infections
1
Healthy
1
Fatty Liver
1
Colorectal Neoplasms
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
36
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
29
Papillomavirus Vaccines
22
Vaccines
11
Human Papillomavirus Recombinant Vaccine nonavalent
11
Radiotherapy, Intensity-Modulated
7
Human Papillomavirus DNA Tests
7
Colposcopy
7
Cisplatin
7
Educational Status
6
Carboplatin
6
Blood Specimen Collection
6
Vaccines, Synthetic
5
Specimen Handling
5
Early Intervention, Educational
5
Vaginal Smears
4
Methods
4
Engerix-B
4
fludarabine
3
epigallocatechin gallate
3
artesunic acid
3
artemisinin
3
Watchful Waiting
3
Surveys and Questionnaires
3
Patient Navigation
3
Paclitaxel
3
Imiquimod
3
Hepatitis A Vaccines
3
Cyclophosphamide
3
halofantrine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Papillomavirus Infections
×
Olive Oil
×
Clear all
NCT02346227
2018-10-12
KINVAV
Universiteit Antwerpen
Phase 3
Completed
327 enrolled